vs
Side-by-side financial comparison of ADAMAS TRUST, INC. (ADAM) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $43.2M, roughly 1.1× ADAMAS TRUST, INC.). ADAMAS TRUST, INC. runs the higher net margin — 124.0% vs -4.8%, a 128.8% gap on every dollar of revenue. On growth, ADAMAS TRUST, INC. posted the faster year-over-year revenue change (61.6% vs -47.3%). ADAMAS TRUST, INC. produced more free cash flow last quarter ($125.9M vs $74.6M). Over the past eight quarters, ADAMAS TRUST, INC.'s revenue compounded faster (55.5% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
ADAM vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.2M | $47.7M |
| Net Profit | $53.5M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | — | 14.3% |
| Net Margin | 124.0% | -4.8% |
| Revenue YoY | 61.6% | -47.3% |
| Net Profit YoY | 270.5% | -200.9% |
| EPS (diluted) | $0.45 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.2M | $47.7M | ||
| Q3 25 | $36.6M | $122.1M | ||
| Q2 25 | $36.4M | $85.2M | ||
| Q1 25 | $33.1M | $41.1M | ||
| Q4 24 | $26.7M | $90.5M | ||
| Q3 24 | $20.2M | $91.6M | ||
| Q2 24 | $19.0M | $94.4M | ||
| Q1 24 | $17.9M | $74.9M |
| Q4 25 | $53.5M | $-2.3M | ||
| Q3 25 | $44.8M | $40.1M | ||
| Q2 25 | $8.5M | $23.6M | ||
| Q1 25 | $42.2M | $-37.4M | ||
| Q4 24 | $-31.4M | $2.3M | ||
| Q3 24 | $42.8M | $3.6M | ||
| Q2 24 | $-15.6M | $-860.0K | ||
| Q1 24 | $-57.9M | $-4.2M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 61.8% | ||
| Q2 25 | 11.7% | 53.2% | ||
| Q1 25 | — | -70.7% | ||
| Q4 24 | -119.0% | 34.8% | ||
| Q3 24 | — | 28.0% | ||
| Q2 24 | -124.7% | 26.5% | ||
| Q1 24 | -448.8% | 14.7% |
| Q4 25 | 124.0% | -4.8% | ||
| Q3 25 | 122.5% | 32.8% | ||
| Q2 25 | 23.4% | 27.7% | ||
| Q1 25 | 127.4% | -90.9% | ||
| Q4 24 | -117.5% | 2.5% | ||
| Q3 24 | 211.7% | 4.0% | ||
| Q2 24 | -81.9% | -0.9% | ||
| Q1 24 | -324.1% | -5.6% |
| Q4 25 | $0.45 | $0.01 | ||
| Q3 25 | $0.36 | $0.23 | ||
| Q2 25 | $-0.04 | $0.14 | ||
| Q1 25 | $0.33 | $-0.23 | ||
| Q4 24 | $-0.46 | $0.03 | ||
| Q3 24 | $0.36 | $0.02 | ||
| Q2 24 | $-0.29 | $-0.01 | ||
| Q1 24 | $-0.75 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $210.3M | $215.5M |
| Total DebtLower is stronger | $735.8M | — |
| Stockholders' EquityBook value | $1.4B | $-261.8M |
| Total Assets | $12.6B | $396.9M |
| Debt / EquityLower = less leverage | 0.52× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $210.3M | $215.5M | ||
| Q3 25 | $185.3M | $140.4M | ||
| Q2 25 | $160.4M | $92.9M | ||
| Q1 25 | $177.1M | $108.5M | ||
| Q4 24 | $167.4M | $88.6M | ||
| Q3 24 | $195.1M | $88.2M | ||
| Q2 24 | $235.5M | $105.5M | ||
| Q1 24 | $226.9M | $121.5M |
| Q4 25 | $735.8M | — | ||
| Q3 25 | $766.6M | $199.5M | ||
| Q2 25 | $653.0M | $199.3M | ||
| Q1 25 | $654.4M | $199.2M | ||
| Q4 24 | $573.2M | $199.0M | ||
| Q3 24 | $699.4M | $198.8M | ||
| Q2 24 | $800.7M | $198.6M | ||
| Q1 24 | $1.0B | $398.3M |
| Q4 25 | $1.4B | $-261.8M | ||
| Q3 25 | $1.4B | $-264.2M | ||
| Q2 25 | $1.4B | $-308.2M | ||
| Q1 25 | $1.4B | $-334.1M | ||
| Q4 24 | $1.4B | $-301.3M | ||
| Q3 24 | $1.4B | $-311.3M | ||
| Q2 24 | $1.4B | $-321.7M | ||
| Q1 24 | $1.5B | $-330.5M |
| Q4 25 | $12.6B | $396.9M | ||
| Q3 25 | $12.4B | $396.1M | ||
| Q2 25 | $10.6B | $342.9M | ||
| Q1 25 | $10.0B | $327.2M | ||
| Q4 24 | $9.2B | $350.9M | ||
| Q3 24 | $8.9B | $389.5M | ||
| Q2 24 | $8.2B | $395.6M | ||
| Q1 24 | $7.4B | $438.8M |
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.56× | — | ||
| Q1 24 | 0.67× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $134.0M | $74.6M |
| Free Cash FlowOCF − Capex | $125.9M | $74.6M |
| FCF MarginFCF / Revenue | 291.6% | 156.3% |
| Capex IntensityCapex / Revenue | 18.9% | 0.0% |
| Cash ConversionOCF / Net Profit | 2.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $134.0M | $74.6M | ||
| Q3 25 | $6.9M | $47.6M | ||
| Q2 25 | $39.2M | $-15.1M | ||
| Q1 25 | $25.8M | $20.0M | ||
| Q4 24 | $14.1M | $15.2M | ||
| Q3 24 | $-922.0K | $9.9M | ||
| Q2 24 | $-993.0K | $33.5M | ||
| Q1 24 | $-13.1M | $45.0M |
| Q4 25 | $125.9M | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | $-10.6M | — | ||
| Q3 24 | $-8.6M | $9.9M | ||
| Q2 24 | $-8.6M | $33.4M | ||
| Q1 24 | $-19.1M | $44.9M |
| Q4 25 | 291.6% | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | -39.6% | — | ||
| Q3 24 | -42.3% | 10.8% | ||
| Q2 24 | -44.9% | 35.4% | ||
| Q1 24 | -107.0% | 60.0% |
| Q4 25 | 18.9% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 92.3% | 0.0% | ||
| Q3 24 | 37.7% | 0.0% | ||
| Q2 24 | 39.7% | 0.1% | ||
| Q1 24 | 33.5% | 0.1% |
| Q4 25 | 2.50× | — | ||
| Q3 25 | 0.15× | 1.19× | ||
| Q2 25 | 4.59× | -0.64× | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | -0.02× | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
IRWD
Segment breakdown not available.
